Otsuka The managing director of Otsuka’s 50-50 joint venture with Turkish giant Abdi Ibrahim, Abdi Ibrahim Otsuka, discusses the mutual advantage the companies can offer each other, and branding Abdi Ibrahim Otsuka as an innovative player on the Turkish arena. What were the initial aspirations in establishing the joint venture between…
World Medicine The founder and chairman of the rapidly expanding World Medicine group of companies discusses his firm’s international expansion strategy, how he came to the decision to invest in production and R&D facilities in Turkey, and the strong support World Medicine has from the Turkish government. How did you originally come…
Menarini Menarini’s Turkish subsidiary, Ibrahim Etem Menarini, has adapted to the current pharmaceutical market and is positioned to grow in several segments including their new OTC business, but is constrained by their current capacity which has minimal excess in some specific lines of production. Uğur Bingöl, the new managing director discusses…
association The chairman of the British Chamber of Commerce in Turkey, the second oldest foreign British chamber in the world, discusses their efforts to increase investment in high value added services in Turkey, particularly R&D, and the domestic production of innovative products. As the the second-oldest British chamber in the world,…
distribution The CEO of ZenithPharma discusses the potential of Africa for Moroccan pharma companies, and what it takes to succeed in the Moroccan pharma market. ZenithPharma’s headquarters are located in Agadir. Why did you choose Agadir? Historically, we started our business in the pharmaceutical industry here when we opened a wholesale…
association The CEO of Morocco’s oldest pharma association discusses the latest regulatory changes in Morocco and their impact on its members, as well as the position of Moroccan pharma in the African and European context. You have significant experience in the pharmaceutical industry in Morocco. What have been the key steps…
access The general manager of Iberma discusses the history of the Moroccan pharmaceutical industry, new measures to improve access, and working on Moroccan-European partnerships in the pharma sector. You have a long experience of the Moroccan pharmaceutical industry. What have been the most significant changes throughout its history? Morocco initiated its…
manufacturing The corporate development director and business development manager of UpPharma explain why Market Expansion Services (MES) model represents a unique business opportunity for firms looking to establish themselves in the Mexican pharmaceutical market, why small and medium sized companies are now considering investing in the country and how the vision…
Doing business The councillor at the Swiss Embassy talks about how the two countries have a particularly close relationship when it comes to pharma, the challenge of introducing innovative products to the Mexican market and why Swiss companies are partnering with both medical academies and the authorities. Could you please introduce the…
doing business The president and founder of Knobloch Information Group, the leading supplier of market data to the pharmaceutical industry in Mexico, provides an in-depth overlook about the most important changes that are reshaping the Mexican pharmaceutical market. Knobloch Information Group is the leading supplier of market data to the pharmaceutical industry…
medical devices Philips aims at becoming the leading provider of solutions across the full ‘continuum of care’. The general manager of the healthcare division in Mexico explains how the company has made customer service, education, software and integrated solutions the strategic pillars to find innovative ways to deliver healthcare. What are the…
doing business The longstanding GM of one of the foremost data management services companies for Romanian healthcare analyses some of the key trends sweeping the industry while at he same time outlining the transformational changes taking place with Cegedim’s own service offering. Since we last sat down with you in 2011, what…
See our Cookie Privacy Policy Here